Novartis AG chief executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against COVID-19, Swiss weekly SonntagsZeitung reported yesterday.
Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which US President Donald Trump also has been promoting, can be approved for use.
Other companies including Bayer AG and Teva Pharmaceutical Industries Ltd have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences Inc is testing its experimental drug remdesivir against COVID-19.
“Pre-clinical studies in animals, as well as the first data from clinical studies, show that hydroxychloroquine kills the coronavirus,” Narasimhan told the newspaper. “We’re working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it’s too early to say anything definitively.”
He said the company is currently looking for additional active drug ingredients to make more hydroxychloroquine, should clinical trials be successful.
Narasimhan said that three other Novartis drugs — Jakavi for cancer, multiple sclerosis drug Gilenya and fever drug Ilaris — are being studied for their effect on complications related to COVID-19, SonntagsZeitung reported.
This follows efforts to repurpose drugs made by Roche Holding AG and Sanofi SA to treat complications related to the disease.
Meanwhile, Gilead is to expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.
The drugmaker said it is switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 COVID-19 patients.
“With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time,” Gilead chairman and CEO Daniel O’Day said in an open letter sent by e-mail on Saturday.
“While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people,” he said.
Remdesivir was developed initially for Ebola and studied in patients in the eastern region of the Democratic Republic of the Congo. Multiple clinical trials are investigating the drug’s effects in COVID-19 patients in China and elsewhere.
Initial results might be reported in the coming weeks, O’Day said.
If approved, the Foster City, California-based company “will work to ensure affordability and access, so that remdesivir is available to patients with the greatest need,” he said.
“The urgency comes from knowing the desperate need among patients and the lack of any approved treatment,” O’Day said. “The responsibility is to ensure that remdesivir, an investigational medicine, is effective and safe before it is distributed for use worldwide,” he said.
Additional reporting by Bloomberg
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
With an approval rating of just two percent, Peruvian President Dina Boluarte might be the world’s most unpopular leader, according to pollsters. Protests greeted her rise to power 29 months ago, and have marked her entire term — joined by assorted scandals, investigations, controversies and a surge in gang violence. The 63-year-old is the target of a dozen probes, including for her alleged failure to declare gifts of luxury jewels and watches, a scandal inevitably dubbed “Rolexgate.” She is also under the microscope for a two-week undeclared absence for nose surgery — which she insists was medical, not cosmetic — and is
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
CHIP DUTIES: TSMC said it voiced its concerns to Washington about tariffs, telling the US commerce department that it wants ‘fair treatment’ to protect its competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reiterated robust business prospects for this year as strong artificial intelligence (AI) chip demand from Nvidia Corp and other customers would absorb the impacts of US tariffs. “The impact of tariffs would be indirect, as the custom tax is the importers’ responsibility, not the exporters,” TSMC chairman and chief executive officer C.C. Wei (魏哲家) said at the chipmaker’s annual shareholders’ meeting in Hsinchu City. TSMC’s business could be affected if people become reluctant to buy electronics due to inflated prices, Wei said. In addition, the chipmaker has voiced its concern to the US Department of Commerce
RSS